Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Equity (2016 - 2025)

Historic Return on Equity for Myriad Genetics (MYGN) over the last 15 years, with Q3 2025 value amounting to 1.05%.

  • Myriad Genetics' Return on Equity fell 9000.0% to 1.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.05%, marking a year-over-year decrease of 9000.0%. This contributed to the annual value of 0.17% for FY2024, which is 1400.0% up from last year.
  • Myriad Genetics' Return on Equity amounted to 1.05% in Q3 2025, which was down 9000.0% from 0.72% recorded in Q2 2025.
  • Myriad Genetics' Return on Equity's 5-year high stood at 0.01% during Q1 2022, with a 5-year trough of 1.05% in Q3 2025.
  • For the 5-year period, Myriad Genetics' Return on Equity averaged around 0.24%, with its median value being 0.17% (2023).
  • Per our database at Business Quant, Myriad Genetics' Return on Equity surged by 2400bps in 2021 and then plummeted by -9000bps in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Return on Equity stood at 0.03% in 2021, then crashed by -342bps to 0.12% in 2022, then plummeted by -189bps to 0.36% in 2023, then soared by 51bps to 0.18% in 2024, then crashed by -492bps to 1.05% in 2025.
  • Its Return on Equity stands at 1.05% for Q3 2025, versus 0.72% for Q2 2025 and 0.14% for Q1 2025.